A single infusion of the experimental CRISPR-Cas9 therapy CTX310 kept LDL cholesterol down 52.5% and triglycerides down 47.8% a year later in a first-in-human trial, with no serious treatment-related adverse events.
A single infusion of the experimental CRISPR-Cas9 therapy CTX310 kept LDL cholesterol down 52.5% and triglycerides down 47.8% a year later in a first-in-human trial, with no serious treatment-related adverse events.